MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 8 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.53)
Consensus Price Target: $36.88 (198.58% upside)

Current Analysts' Coverage Summary for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetActions
2/10/2016OppenheimerReiterated RatingOutperform$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Piper JaffrayReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/1/2016WedbushReiterated RatingOutperform$32.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016SunTrustLower Price TargetNeutral$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Robert W. BairdReiterated RatingOutperform$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016RBC CapitalDowngradeOutperform -> Sector Perform$62.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016Needham & Company LLCReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/15/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/25/2015Jefferies GroupReiterated RatingHold$28.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/22/2015WBB SecuritiesReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/23/2015Bank of AmericaInitiated CoverageBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/1/2015SusquehannaBoost Price TargetNeutral$33.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Deutsche BankReiterated RatingHold$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Credit SuisseReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2014Citigroup Inc.UpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2014SidotiInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/12/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by the American Association of Individual Investors As Featured by Seeking Alpha